Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer:targeting the androgen receptor-regulated tumor immune microenvironment

作     者：Bisheng Cheng Hai Huang Bisheng Cheng;Hai Huang

作者机构：Department of UrologySun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China 

出 版 物：《癌症生物学与医学:英文版》 (Cancer Biology & Medicine)

年 卷 期：2023年第20卷第8期

页      面：568-574页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：Support was provided by the National Natural Science Foundation of China(Grant Nos.81974395 and 82173036) Guangdong Basic and Applied Basic Research Foundation(Grant No.2019A1515011437) International Science and Technology Cooperation Project Plan of Guangdong Province(Grant No.2021A0505030085) Sun Yat-Sen University Clinical Research 5010 Program(Grant No.2019005) Sun Yat-Sen Clinical Research Cultivating Program(Grant No.201702) Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation(Grant No.2020B1212060018OF006) Guangdong Provincial Clinical Research Center for Urological Diseases(Grant No.2020B1111170006) Beijing Bethune Charitable Foundation(Grant No.mnzl202001) Guangzhou Science and Technology Key R&D Project(Grant No.202206010117) Beijing CSCO Clinical Oncology Research Foundation(Grant No.Y-tongshu2021/ms-0162) National Key Research and Development Program of China(Grant No.2022YFC3602900) 

主　　题：therapeutic cancer resistance 

摘      要：Castration-resistant prostate cancer(CRPC)poses a major treatment challenge,because disease progression occurs despite androgen deprivation therapy(ADT)*** therapeutic resistance in CRPC remains a critical unmet need in clinical *** androgen receptor(AR)signaling pathway plays a critical role in prostate cancer development and progression,and is also involved in regulating the tumor immune microenvironment(TIME).